Adrenomedullin optimises mortality prediction in COPD patients

Marjolein Brusse-Keizer, Maaike Zuur-Telgen, Jacobus Adrianus Maria van der Palen, Paul van der Valk, Huib Kerstjens, Wim Boersma, Francesco Blasi, Konstantinos Kostikas, Branislava Milenkovic, Michael Tamm, Daiana Stolz

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
37 Downloads (Pure)

Abstract

Background: Current multicomponent scores that predict mortality in COPD patients might underestimate the systemic component of COPD. Therefore, we evaluated the accuracy of circulating levels of proadrenomedullin (MR-proADM) alone or combined with the ADO (Age, Dyspnoea, airflow Obstruction), updated ADO or BOD (Body mass index, airflow Obstruction, Dyspnoea) index to predict all-cause mortality in stable COPD patients. Methods: This study pooled data of 1285 patients from the COMIC and PROMISE-COPD study. Results: Patients with high MR-proADM levels ( 0.87 nmol/l) had a 2.1 fold higher risk of dying than those with lower levels (p < 0.001). Based on the C-statistic, the ADOA index (ADO plus MR-proADM) (C Z 0.72) was the most accurate predictor followed by the BODA (BOD plus MR-proADM) (C Z 0.71) and the updated ADOA index (updated ADO plus MRproADM) (C Z 0.70). Adding MR-proADM to ADO and BOD was superior in forecasting 1- and 2-year mortality. The net percentages of persons with events correctly reclassified (NRIþ) within respectively 1-year and 2-year was 31% and 20% for ADO, 31% and 20% for updated ADO and 25% and 19% for BOD. The net percentages of persons without events correctly reclassified (NRI-) within respectively 1-year and 2-year was 26% and 27% for ADO, 27% and 28% for updated ADO and 34% and 34% for BOD. Conclusions: Adding MR-proADM increased the predictive power of BOD, ADO and updated ADO index.
Original languageEnglish
Pages (from-to)734-742
Number of pages9
JournalRespiratory medicine
Volume109
DOIs
Publication statusPublished - 2015

Keywords

  • IR-97231
  • METIS-311779

Fingerprint Dive into the research topics of 'Adrenomedullin optimises mortality prediction in COPD patients'. Together they form a unique fingerprint.

Cite this